Cargando…

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

SIMPLE SUMMARY: Although multiple meta-analyses on active specific immunotherapy treatment for glioblastoma multiforme (GBM) have demonstrated a significant prolongation of overall survival, no single research group has succeeded in demonstrating the efficacy of this type of treatment in a prospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Gool, Stefaan W., Makalowski, Jennifer, Fiore, Simon, Sprenger, Tobias, Prix, Lothar, Schirrmacher, Volker, Stuecker, Wilfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796083/ https://www.ncbi.nlm.nih.gov/pubmed/33374196 http://dx.doi.org/10.3390/cancers13010032

Ejemplares similares

Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
por: Van Gool, Stefaan W., et al.
Publicado: (2023)

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
por: Van Gool, Stefaan W., et al.
Publicado: (2022)

Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
por: Van Gool, Stefaan W., et al.
Publicado: (2020)

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
por: Schirrmacher, Volker, et al.
Publicado: (2022)

DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN
por: Van Gool, Stefaan, et al.
Publicado: (2020)

Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
por: Schirrmacher, Volker, et al.
Publicado: (2020)

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
por: Schirrmacher, Volker, et al.
Publicado: (2019)

Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
por: Van Gool, Stefaan W., et al.
Publicado: (2023)

The Application of Evidence-Based Medicine in Individualized Medicine
por: Van de Vliet, Peter, et al.
Publicado: (2023)

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH
por: Kampers, Linde F C, et al.
Publicado: (2023)

Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
por: SCHIRRMACHER, VOLKER, et al.
Publicado: (2014)

Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
por: van Woensel, Matthias, et al.
Publicado: (2013)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
por: Ion-Margineanu, Adrian, et al.
Publicado: (2015)

Brain Tumor Immunotherapy: What have We Learned so Far?
por: Van Gool, Stefaan Willy
Publicado: (2015)

Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM
por: Liu, Bao, et al.
Publicado: (2022)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

The role of neurosurgery in medulla oblongata GBM, a challenge
por: Fahlbusch, Rudolf
Publicado: (2019)

CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement
por: Pant, Ayush, et al.
Publicado: (2023)

Anti-GBM-Nephritis
por: Windpessl, Martin, et al.
Publicado: (2023)

Assessing the Role of STAT3 in DC Differentiation and Autologous DC Immunotherapy in Mouse Models of GBM
por: Assi, Hikmat, et al.
Publicado: (2014)

Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM
por: Liu, Ching-Ann, et al.
Publicado: (2022)

Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival
por: Belmans, Jochen, et al.
Publicado: (2017)

Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features
por: Rios Velazquez, Emmanuel, et al.
Publicado: (2015)

Differentiation of Human GBM From Non-GBM Brain Tissue With Polarization Imaging Technique
por: Liu, Yi-Rong, et al.
Publicado: (2022)

Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells
por: Mukherjee, Sumit, et al.
Publicado: (2018)

Advances in nanotechnology for the treatment of GBM
por: Wei, Dongyan, et al.
Publicado: (2023)

Anti-GBM disease with a mild relapsing course and low levels of anti-GBM autoantibodies
por: Segelmark, Mårten, et al.
Publicado: (2012)

Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines
por: Binder, Zev A., et al.
Publicado: (2016)

Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM
por: Feng, Songshan, et al.
Publicado: (2022)

Transformation of membranous into anti-GBM nephritis
por: Imtiaz, S., et al.
Publicado: (2012)

Mitochondrial DNA Alterations in Glioblastoma (GBM)
por: Leão Barros, Mariceli Baia, et al.
Publicado: (2021)

The Role of Myeloid Cells in GBM Immunosuppression
por: Lin, Ya-Jui, et al.
Publicado: (2022)

90K predicts the prognosis of glioma patients and enhances tumor lysate-pulsed DC vaccine for immunotherapy of GBM in vitro
por: Zeng, Yu, et al.
Publicado: (2021)

Histone H3 Phosphorylation in GBM: a New Rational to Guide the Use of Kinase Inhibitors in anti-GBM Therapy
por: Pacaud, Romain, et al.
Publicado: (2015)

Anti-GBM disease with positive serum anti-GBM antibodies but negative IgG deposition: A case report
por: Kazemzadeh, Kimia, et al.
Publicado: (2023)

Immunotherapy trials in Parkinson’s disease: challenges
por: Xiao, Bin, et al.
Publicado: (2023)

Podocyte Depletion in Thin GBM and Alport Syndrome
por: Wickman, Larysa, et al.
Publicado: (2016)

Re-thinking the preclinical development of GBM therapeutics
por: Cosset, Érika, et al.
Publicado: (2018)

Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vm07g1vrjkgidf1jjj6lqld23n